This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
How do you identify your ZINFORO® patients with cSSTI?1-5,*
Zinforo® cSSTI patient profiles6,7,*
Patient 1: Patient with diabetes having a cSSTI
A 62-year-old female with diabetes presents with deep and extensive cellulitis on the right leg that extends from the mid-calf to the ankle.
Patient presentation, history and risk factors
Patient 2: Patient with cSSTI having renal insufficiency†
A 67-year-old male presents with a painful, fluctuant and gluteal abscess.
Patient presentation, history and risk factors:
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which ZINFORO® could be considered.
*There is no experience with Zinforo® in the treatment of cSSTI in the following patient groups:
The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.8
†Zinforo® is primarily excreted by the kidneys and the dose should be reduced in patients with moderate to severe renal insufficiency.8
CAP, community-acquired pneumonia; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; BMI, body mass index; HbA1c, haemoglobin A1c; ICU, intensive care unit; PVD, peripheral vascular disease.
References:
Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ZFO-IND-0417 June 2022
Simple dosing with a flexible infusion time
Proven clinical efficacy in patients with
CAP and cSSTI
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.